Article Text

Download PDFPDF
Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant
  1. Thomas Sherman and
  2. Vasant Raman
  1. Royal Eye Infirmary, University hospitals of Plymouth NHS Trust, Plymouth, UK
  1. Correspondence to Vasant Raman, vasant.raman{at}


Ozurdex (Allergan, Irvine, California, USA) is a biodegradable sustained release intravitreal implant containing 0.7 mg dexamethasone in a solid polymer drug delivery system. In the UK, it is approved for use in patients with macular oedema secondary to retinal vein occlusion, diabetic maculopathy and non-infectious uveitis. Although the implant is meant to be injected into the vitreous cavity, it can be inadvertently injected into the crystalline lens. This can also migrate into the anterior chamber, under altered anatomical conditions of the anterior segment. We report a case of incompletely penetrated dexamethasone implant, in a patient undergoing treatment for macular oedema secondary to retinal vein occlusion. The partially penetrated implant was managed conservatively with a good outcome.

  • macula
  • retina

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TS was involved in following up the patient and also involved in collecting data and initial draft of the case report. VR was involved in concept of the case report, management of the patient and finalising the draft and proof reading of the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.